IRIS
STEFANI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 56.452
EU - Europa 4.020
AS - Asia 1.865
Continente sconosciuto - Info sul continente non disponibili 24
SA - Sud America 24
OC - Oceania 5
AF - Africa 2
Totale 62.392
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 56.420
SG - Singapore 1.119
IE - Irlanda 1.002
UA - Ucraina 837
DE - Germania 555
CN - Cina 510
IT - Italia 400
FR - Francia 337
SE - Svezia 208
GB - Regno Unito 195
RU - Federazione Russa 145
KR - Corea 144
FI - Finlandia 139
PL - Polonia 117
CA - Canada 26
EU - Europa 23
JP - Giappone 22
BE - Belgio 21
IN - India 16
BR - Brasile 13
KG - Kirghizistan 13
VN - Vietnam 13
CZ - Repubblica Ceca 12
NL - Olanda 8
CL - Cile 7
RO - Romania 7
UZ - Uzbekistan 6
CH - Svizzera 5
PT - Portogallo 5
AL - Albania 4
AT - Austria 4
AU - Australia 4
BG - Bulgaria 4
ES - Italia 4
HK - Hong Kong 4
DM - Dominica 3
GR - Grecia 3
IL - Israele 3
MX - Messico 3
SK - Slovacchia (Repubblica Slovacca) 3
CO - Colombia 2
DK - Danimarca 2
EG - Egitto 2
IQ - Iraq 2
IR - Iran 2
MY - Malesia 2
PE - Perù 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BY - Bielorussia 1
GE - Georgia 1
ID - Indonesia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
Totale 62.392
Salva come PNG Salva come JPEG
Città #
Wilmington 15.908
Houston 15.105
Woodbridge 14.022
Fairfield 2.261
Ann Arbor 1.123
Singapore 983
Ashburn 957
Seattle 873
Jacksonville 768
Cambridge 767
Chandler 726
Dublin 662
Medford 509
Dearborn 413
Santa Clara 289
Beijing 262
Lawrence 235
Rome 150
New York 118
San Diego 115
Kraków 110
Menlo Park 110
Moscow 71
London 50
Mülheim 49
Norwalk 44
Redwood City 40
Milan 39
Zhengzhou 37
Munich 32
Hefei 30
Seoul 28
Palo Alto 27
Durham 26
Verona 25
Shanghai 22
Brussels 21
Falls Church 21
Kunming 21
Nanjing 21
Mountain View 20
Toronto 19
University Park 19
Helsinki 18
St Louis 18
Boardman 17
Phoenix 16
San Jose 15
Creede 14
Kilburn 12
Mcallen 12
Saint Petersburg 12
Brno 11
Hounslow 11
Redmond 11
Chengdu 10
Engelhard 10
Jinan 10
Monmouth Junction 10
Nuremberg 10
Council Bluffs 9
Detroit 9
Guangzhou 9
Del Norte 8
Dong Ket 8
Garden City 8
Hangzhou 8
Campi Bisenzio 7
Changsha 7
Los Angeles 7
Pune 7
Atlanta 6
Chiswick 6
Edinburgh 6
Genoa 6
Hattiesburg 6
Islington 6
San Mateo 6
Shenyang 6
Warsaw 6
Hanoi 5
Lagoa de São Francisco 5
Lappeenranta 5
Nanchang 5
Philadelphia 5
Reggio Calabria 5
Tokyo 5
Wuhan 5
New Bedfont 4
Palermo 4
Quzhou 4
Santarém 4
St. George 4
São Paulo 4
Turin 4
Augusta 3
Bielefeld 3
Chicago 3
Chongqing 3
Como 3
Totale 57.569
Salva come PNG Salva come JPEG
Nome #
CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia 441
Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus 440
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. 439
AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis 433
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. 431
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission 430
Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a natural population of cognitive intact Parkinson's Disease patients. 430
Selective vulnerability of pallidal neurons in the early phases of manganese intoxication 428
Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms 428
The pharmacological blockade of medial forebrain bundle induces an acute pathological synchronization of the cortico-subthalamic nucleus-globus pallidus pathway. 420
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia 420
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease 418
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 417
Acute nigro-striatal blockade alters cortico-striatal encoding: An in vivo electrophysiological study 415
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease 415
Acute inactivation of the medial forebrain bundle imposes oscillations in the SNr: a challenge for the 6-OHDA model? 414
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment 414
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration 411
Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process 408
Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease 408
Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease 407
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature 406
Deep brain stimulation of CM/PF of thalamus could be the new elective target for tremor in advanced Parkinson's Disease? 406
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart 402
The clinical efficacy of L-DOPA and STN-DBS share a common marker: reduced GABA content in the motor thalamus 402
Distinct roles of cortical and pallidal β and γ frequencies in hemiparkinsonian and dyskinetic rats 402
Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. 401
Opioid-mediated modulation of calcium currents in striatal and pallidal neurons following reserpine treatment: focus on kappa response. 399
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease 399
Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson disease patients: one-year follow-up. 398
Therapy for dyskinesias in Parkinson’s disease patients 396
Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease 395
Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives 394
Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease 392
Posterior cortical atrophy with unilateral occipito-temporal degeneration 392
Subthalamic stimulation and levodopa modulate cortical reactivity in Parkinson's patients 392
Differential post-translational modifications of transthyretin in Alzheimer's disease: A study of the cerebral spinal fluid. 391
A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices 391
Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson's disease patients, but its action is related to modality and site of stimulation 391
Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT 391
Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. 390
Outward potassium currents activated by depolarization in rat globus pallidus 390
Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease 389
Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents 389
Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study 389
Pathological gambling from dopamine agonist and deep brain stimulation of the nucleus tegmenti pedunculopontine 389
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. 388
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations 387
Vulnerability of medium spiny striatal neurons to glutamate: role of Na+/K+ ATPase 385
Thalamic ¹²³I FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression 380
Neurotensin effects on N-type calcium currents among rat pallidal neurons: an electrophysiological and immunohistochemical study. 380
Association analysis between Alzheimer's disease and the Nicastrin gene polymorphisms 379
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 378
Activation of metabotropic glutamate receptors inhibits calcium currents and GABA-mediated synaptic potentials in striatal neurons 378
The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease 377
Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients 376
In vivo electrophysiology of dopamine-denervated striatum: focus on the nitric oxide/cGMP signaling pathway. 375
The modulation of dopamine receptors in rat striatum 373
Basic research in substantia nigra and ventral tegmental area: clinical implications 373
The modulation of calcium currents by the activation of mGluRs. Functional implications 369
Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on "CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease" by Lista et al 369
D2-mediated modulation of N-type calcium currents in rat globus pallidus neurons following dopamine denervation 368
Subdyskinetic apomorphine responses in globus pallidus and subthalamus of parkinsonian patients: lack of clear evidence for the 'indirect pathway' 368
Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain 366
Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects 365
Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology 365
Catecholamine-based treatment in AD patients: expectations and delusions 365
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD 364
Theta Burst Stimulation Modulates Cerebellar-Cortical Connectivity in Patients with Progressive Supranuclear Palsy 364
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder 364
Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ¹²³I-MIBG. 363
Alexithymia is a non-motor symptom of Parkinson disease 361
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. 360
Deep brain stimulation in Parkinson's disease patients: biochemical evidence 357
The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients 356
Re: Stereotactic microdialysis of the basal ganglia in Parkinson's disease 355
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients 355
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease 354
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.(Reply from the authors) 353
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment 352
Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease 351
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids 349
Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease 347
Association study of the 5-hydroxytryptamine(6) receptor gene in Alzheimer's disease 345
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms 343
Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? 343
CSF biomarker variability in the Alzheimer's Association quality control program 343
L-dopa modulates motor cortex excitability in Alzheimer's disease patients 342
Reduced GABA Content in the Motor Thalamus during effective deep brain stimulation of the subthalamic nucleus 340
Electrophysiological actions of felbamate on rat striatal neurones 340
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers 339
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 338
Cardiac rhabdomyosarcoma: a clinicopathologic and electron microscopy study 337
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients 336
Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease? 332
Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits 332
Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson's disease patients 328
Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease 328
Multi-target strategy for Parkinsonian patients: the role of deep brain stimulation in the centromedian-parafascicularis complex. 327
Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD 327
Totale 38.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.174
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202015.597 0 0 0 2.045 1.804 2.177 1.724 1.815 1.804 1.655 1.206 1.367
2020/202110.978 1.309 1.390 1.315 1.352 1.062 1.219 1.240 1.008 256 211 514 102
2021/20222.888 60 357 142 125 89 153 613 148 136 143 238 684
2022/20232.237 277 161 80 219 170 611 251 124 170 6 120 48
2023/2024882 93 34 67 19 88 149 36 144 22 57 14 159
2024/20252.130 175 1.311 613 31 0 0 0 0 0 0 0 0
Totale 63.305